Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series.
Journal of Affective Disorders April 1, 2023 Olivier Payette, P. Lespérance, V. D. Jodoin et al. 7 citations
For people with treatment-resistant depression who did not benefit from transcranial magnetic stimulation (TMS), intravenous racemic ketamine may offer some help. In a small case series of 21 patients, a course of six ketamine infusions over two weeks was safe and produced few side effects. Average depression scores, measured by the MADRS scale, fell from 27.6 (moderate depression) to 18.6 (mild depression), a mean improvement of 34.5%. Four patients (19%) responded to treatment, and two of those (9.5%) achieved remission. The study was uncontrolled and retrospective, so results are preliminary.